MiRXES eyes fuss-free early cancer tests; road ahead not easy
Local startup, which is heading towards a public listing, is doubling down on its acquisition strategy after a US$77m funding round
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
IMAGINE if early-stage cancer testing was as fuss-free as taking a Covid PCR test or a blood test.
Homegrown startup MiRXES is hoping to bring such "liquid" cancer tests into our homes in about 5 to 10 years' time. If this dream pans out, a simple blood test could be able to detect all types of cancers at an early stage - when it is easier to treat and possibly cure.
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
TRENDING NOW
From 1MDB to ‘corporate mafia’: Is Malaysia facing a new governance test?
Higher costs, lower returns: Why are Singaporeans still betting on real estate?
South-east Asian markets account for 8.8% of global capital inflows from 2021 to 2024: report
Richard Eu on how core values, customers keep Singapore’s TCM chain Eu Yan Sang relevant
